Latest Ratios: P/E Ratio -6.6x · EV/EBITDA N/A · ROE -32.4%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $87M | $92M | $18M | $17M | $22M | $53M | $49M | $43M | $15M | $136M | $87M |
| Enterprise Value | $84M | $89M | $15M | $14M | $20M | $40M | $30M | $16M | $10M | $126M | $85M |
| P/E Ratio → | -6.55 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.12 | 1.18 | 4.96 | 3.72 | 3.00 | 3.71 | 2.02 | 1.38 | 11.53 | 13.69 | 51.41 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -32.4% | -32.4% | -285.0% | -182.2% | -121.5% | -58.5% | -32.8% | -44.1% | -128.6% | -130.2% | -1418.9% |
| ROA | -30.0% | -30.0% | -159.4% | -120.2% | -100.1% | -52.6% | -28.9% | -33.5% | -84.9% | -105.5% | -78.6% |
| ROIC | -29.5% | -29.5% | -624.8% | -197.2% | -293.0% | -242.0% | -149.1% | — | — | — | — |
| ROCE | -36.1% | -36.1% | -286.6% | -164.1% | -119.4% | -57.2% | -31.8% | -43.1% | -122.6% | -80.6% | -81.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.03 | 0.05 | 0.06 | 0.05 | 0.03 | 0.03 | — | — | 0.04 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.85 | -0.50 | -0.28 | -0.89 | -0.77 | -0.88 | -3.94 | -1.08 | -1.55 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -113.61 | -69.36 | — | -22.13 | -28.85 |
Net cash position: cash ($4M) exceeds total debt ($865000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 23.33 | 23.33 | 2.37 | 2.09 | 4.26 | 8.00 | 18.78 | 7.45 | 1.23 | 20.70 | 4.23 |
| Quick Ratio | 23.16 | 23.16 | 2.37 | 2.09 | 4.26 | 8.00 | 18.78 | 7.45 | 1.23 | 20.70 | 4.23 |
| Cash Ratio | 22.97 | 22.97 | 2.22 | 1.69 | 4.00 | 7.81 | 18.33 | 6.48 | 1.10 | 20.43 | 3.46 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $46M | $16M | $10M | $7M | $7M | $7M | $4M | $9M | $9M | $952886 |
Critical cash runway depletion
As reported in financial statements, Microbot's ROIC has remained consistently negative, bottoming out at -130.3% in 2024Q4, which underscores the company's inability to generate productive returns on invested capital while it remains in the high-cost, pre-commercial development phase of its robotic surgical platform.
The persistent negative ROIC trend suggests that every dollar of capital deployed is currently destroying value rather than compounding it, which is typical for early-stage medical technology firms. Investors should monitor whether the recent shift toward clinical trials can eventually stabilize these returns as the company moves closer to potential commercialization.
Based on the provided data, Microbot's cash conversion cycle reached 692 days in 2026Q1, a figure that highlights the extreme inefficiency of managing long-term R&D projects without a steady stream of revenue to offset the lengthy development and procurement timelines inherent in medical robotics.
The exceptionally high days inventory outstanding and long cash conversion cycle suggest that the company is currently holding significant resources tied up in prototyping and clinical preparation. This lack of operational velocity warrants further investigation into whether the company can streamline its supply chain once the Liberty system reaches a commercial manufacturing scale.
According to recent quarterly filings, the company's current ratio has fluctuated wildly, dropping from 27.53 in 2025Q3 to 22.59 in 2026Q1, which indicates that while the firm maintains a high nominal liquidity, its actual cash runway is rapidly depleting due to ongoing operational burn.
The high current ratio is somewhat deceptive, as it reflects the accumulation of assets from dilutive financing rather than operational success. Given the company's reliance on external capital, the liquidity position appears vulnerable to any delays in clinical milestones that would necessitate further equity issuance.
As indicated by market pricing, investors often incorrectly apply traditional P/S or EV/EBITDA multiples to Microbot, which obscures the reality that the company is currently a pre-revenue development entity rather than a mature medical device manufacturer with established cash flows.
Using standard valuation metrics for this business model is fundamentally flawed because it ignores the binary nature of clinical trial outcomes and the potential for non-dilutive milestone payments. A more appropriate framework would involve assessing the probability-weighted net present value of the Liberty system's future market opportunity rather than relying on historical or peer-based multiples.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MBOT stock.
Microbot Medical Inc.'s current P/E ratio is -6.6x. This places it at the 50th percentile of its historical range.
Microbot Medical Inc.'s return on equity (ROE) is -32.4%. The historical average is -110.4%.
Based on historical data, Microbot Medical Inc. is trading at a P/E of -6.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.